Glibenclamide alters interleukin-8 and interleukin-1β of primary human monocytes from diabetes patients against Mycobacterium tuberculosis infection.
Sign Up to like & getrecommendations! Published in 2020 at "Tuberculosis"
DOI: 10.1016/j.tube.2020.101939
Abstract: Type 2 diabetes mellitus (T2DM) is an important risk factor for development of tuberculosis (TB). Our previous study showed glibenclamide, an anti-diabetic drug used to control blood glucose concentration, reduced interleukin (IL)-8 secretion from primary… read more here.
Keywords: monocytes diabetes; human monocytes; infection; tuberculosis ... See more keywords